Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LAW, AVO

Association of American Physicians & Surgeons (AAPS) Sues the FDA to End Its Arbitrary Restrictions on Hydroxychloroquine


TUCSON, Ariz., June 2, 2020 /PRNewswire/ -- Today the Association of American Physicians & Surgeons (AAPS) filed a lawsuit, AAPS v. FDA, against the Food and Drug Administration to end its arbitrary interference with the use of hydroxychloroquine (HCQ), which President Trump and other world leaders have taken as a prophylaxis against COVID-19.

Two million doses of HCQ are being sent by the Trump Administration to Brazil to help medical workers there safeguard themselves against the spread of the virus. But at the same time the FDA continues to block Americans' access to this medication.

HCQ has been approved as safe by the FDA for 65 years, and the CDC states on its website that "CDC has no limits on the use of hydroxychloroquine for the prevention of malaria."

More than 150 million doses have been donated to the strategic national stockpile controlled by the federal government, but unjustified FDA restrictions limit its use to only hospitalized patients for whom a clinical study is unavailable. Hospitals are even returning HCQ to the stockpile because they are not able to use it effectively.

"It is shocking that medical workers in Brazil will have access to HCQ as a prophylaxis while Americans are blocked by the FDA from accessing the same medication for the same use," observes AAPS Executive Director Jane Orient, M.D.

"There is no legal or factual basis for the FDA to limit use of HCQ," states AAPS General Counsel Andrew Schlafly. "The FDA's restrictions on HCQ for Americans are completely indefensible in court."

Many foreign nations, including China, India, South Korea, Costa Rica, United Arab Emirates, and Turkey, use HCQ for early treatment and prevention of COVID-19, AAPS points out.

"Entrenched, politically biased officials at the FDA should not be allowed to interfere with Americans' right to access medication donated to the federal government for public use," Schlafly says. "By preventing Americans' use of HCQ as a prophylaxis, the FDA is infringing on First Amendment rights to attend religious services or participate in political events such as political conventions, town halls, and rallies in an important election year."

"FDA Commissioner Stephen Hahn states that the FDA does not interfere with physicians' ability to prescribe HCQ, and yet at the same time the FDA denies access by millions of Americans to 150 million doses of it in the national stockpile," Schlafly adds. "This irrational hoarding by government is an abuse of power."

The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.

SOURCE Association of American Physicians and Surgeons (AAPS)


These press releases may also interest you

at 10:05
Gibson, Dunn & Crutcher LLP and Barrasso Usdin Kupperman Freeman & Sarver, LLC announce the filing of a civil rights action on behalf of Tayjha Alfred against Martin Bofill ("Bo") Duhé, the District Attorney for the 16th Judicial District of...

at 10:01
The global Control Valve market is expected to grow from USD 10.0 billion in 2024 to USD 13.0 billion by 2029, registering a CAGR of 5.4% according to a new report by MarketsandMarketstm. The global market for control valves has experienced...

at 10:00
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...

at 09:49
Adyton Resources Corporation is pleased to report that on closing the recently announced C$1.5M financing, work activities on its 100% owned Feni Island Gold-Copper Project have commenced in earnest with the engagement of globally renowned...

at 09:45
AM Best has revised the outlook to positive from stable for the Long-Term Issuer Credit Rating (Long-Term ICR) and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Shinkong Insurance Company...



News published on and distributed by: